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Introduction Materials and methods




Mul:ple$ pregnancies$ are$ associated$ with$ an$ increased$ spontaneous$ fetal$ loss$ and$ a$ higher$ rate$ of$ chromosomal$ abnormali:es.$Moreover,$ the$ number$ of$
mul:ple$ pregnancies$ has$ risen$ in$ recent$ years,$ probably$ related$ to$ the$ higher$ u:liza:on$ of$ in# vitro$ fecunda:on$ techniques.$ A$ higher$ frac:on$ of$ these$







PubMed$ database.$ I$ have$ preferably$ chosen$ recent$ ar:cles$ about$ this$ topic,$
most$of$them$from$2011$and$later,$with$a$few$excep:ons.$
$
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1.   Total, DNA, quanBﬁcaBon:, absorbance$ at$
260nm$ or$ ß8globin$ quan:ﬁca:on$ by$ RT8PCR$
of$maternal$ plasma.$ It’s$ used$ to$ ensure$ the$
quality$of$the$collected$DNA.$













1.   Genom i c, r e p r e s en t aBon, o f, e a c h,
chromosome,(chrT).,
2.   CorrecBon,for,GC,content.,
3.   ChrT,zSscore:,>3$ indicates$ trisomy$ in$at$ least$
one$fetus.$





be$ only$ determined$ non8invasively$ on$ the$
ﬁrst$trimester$by$ultrasounds.$
$
•  Zygosity:, refers$ to$ the$ gene:c$ iden:ty$ of$
each$ twin.$ It$ has$ to$ be$ inferred$ from$
chorionicity.$
Results
CONFIRMATION OF TWIN ZYGOSITY BY GENOTYPIC ANALYSIS
We compared the genotypes across approximately
900 000 SNPs for the samples of cord blood from each
twin pair to ascertain if the twins were monozygotic or
dizygotic. We confirmed that the MCDA and MCMA
twins were monozygotic because !99.6% of the SNP
sites were concordant for ach pair of twins. We con-
cluded that all th DCDA twins in our cohort were
dizygotic because the genotype concordance rates were
75.6%–80.3% (Table 1).
DISTRIBUTIONS OF APPARENT FRACTIONAL FETAL DNA
CONCENTRATIONS BETWEEN CHROMOSOMES
We sequenced a median of 431 " 106 raw paired-end
reads (range, 418" 106 to 456" 106) per sample and
obtained a median of 330 " 106 aligned paired-end
reads (range, 228 " 106 to 359 " 106) per sample.
Paired-end reads with identical start and end coordi-
nates in the genome were removed.We achieved a me-
dian of 530-fold coverage (range, 346- to 835-fold) for
each SNP locus for each sample. We used the informa-
tive SNPs identified by FetalQuant to calculate the ap-
parent fractional fetal DNA concentrations across
chromos mes for each maternal plasma DNA sample.
The median number of informative SNPs was 7250
(range, 6495–8409), and 97% of these SNPs were con-
cordant with the microarray data. We determined the
mean, SD, and range for the apparent fractional fetal
DNA concentrations among the chromosomes for
each case. The apparent fractional fetal DNA concen-
tration was relatively constant across chromosomes for
all sets of monozygotic twins, with SD values ranging
Identified by:




























Apparent fractional fetal DNA concentration (%)
Fig. 2. Schematic diagram illustrating the determination of the fractional fetal DNA concentration for each fetus in
the twin pair.
The x axis is the apparent fractional fetal DNA concentration in the 1000-SNP windows. The y axis is the frequency at which
a particular fetal DNA concentration occurs. The distribution of fractional fetal DNA concentrations is characterized by 3 peaks.
The peak with the highest apparent fractional fetal DNA concentration (f) reflects the combined contributions from both fetuses
(f1 # f2). The underlying genotypes for this value include the mother (AA), fetus I (AB), and fetus II (AB). The peaks with lower
concentration values reflect the DNA contributions of individual fetuses (f1 or f2). The underlying genotypes for these values
include the mother (AA), fetus I (AA), and fetus II (AB); or the mother (AA), fetus I (AB), and fetus II (AA). The concentration
for f1 # f2 is identified by searching for the maximal mean f value across windows of 1000 SNPs (fmax). Because fmax $ f1 #
f2, we obtain f2 $ fmax % f1; consequently, only 1 variable, f1, needs to be determined. The binomial-mixture model is used
to resolve f1 to determine the fetal DNA concentration that has the highest likelihood of producing the known combined total
amounts (fmax).
Noninvasive Prenatal Determination of Twin Zygosity










Fetal$ DNA$ derives$ from$ placental$ trophoblas:c$
cells.$ As$ there$ could$ be$ mosaicism$ between$
placenta$and$fetus,$the$chorionicity$determina:on$
could$ allow$ beQer$ diagnosis,$ although$ it’s$ not$
currently$used.$
$
Furthermore,$ it$ has$ not$ been$ shown$ any$
rela:onship$ between$ chorionicity$ and$ fetal$ DNA$
concentra:on.$
MPS$ is$ the$most$used$sequencing$method.$Other$ techniques$
that$could$be$used$are:$
$
•  Digital, PCR:, several$ simultaneously$ ampliﬁca:ons.$ High$
frac:onal$ fetal$DNA$ is$needed.$ It’s$unlikely$ to$be$used$on$
mul:ple$pregnancies.$
•  Targeted,sequencing:,SNP8$or$non8SNP8based$approaches.$
They$ provide$ fast$ and$ accurate$ results$ and$ could$ be$ an$
adequate$alterna:ve$method.,
by MPS [21,23]. Another approach involves the use of highly-
multiplexed PCR to amplify !20 000 SNPs on chromosomes
13, 18, 21, X, and Y before MPS [10,22]. This latter method
uses the parental genotypes and recombination frequencies
to generate billions of possible fetal genotype results. Based
on the sequencing results, the algorithm calculates the rela-
tive likelihood for each hypothesis and to deduce the chance
of aneuploidy (Figure 2B).
A further targeted sequencing approach, DANSR (digi-
tal analysis of selected regions) method has been reported
[9]. For each chromosome, assays were designed against
384 loci involving a set of three locus-specific oligonucleo-
tides. These oligonucleotides were pooled together to allow
the simultaneous pooling and multiplexed sequencing of
selected loci from the chromosomes of interest. Using the
measured fetal fraction, the FORTE (fetal-fraction opti-
mized risk of trisomy evaluation) algorithm is used to
c lculate the risk of the fetal aneuploidy for that case
by calcula ing the chromosome 21 to reference chromo-
some ratio (Figure 2C). More recently, this approach has
been converted to be analyzable using a microarray plat-
form [24]. However, more independent validation will be
necessary to compare the relative robustness of this new
microarray-based protocol [24] versus the previous se-
quencing-based protocol [25].
These initial proof-of-concept studies were rapidly fol-
lowed by multiple large-scale validation studies [26–
31]. As a result, this approach has been rapidly commer-
cialized since the end of 2011. Gil et al. reviewed the
performance of tests from the published data from
2011 to the end of 2013 and calculat d the detection rate
of risomy 21 to be 99% with a false-positive rate of 0.08%
[32]. To date, aneuploidy testing using MPS of maternal
plasma is estimated to be available in over 60 countries
[33] and has been used to test at least 750 000 cases.
Subchromosomal aberrations
Following the success of chromosomal aneuploidy detec-
tion, subchromosomal aberrations became the next target
for NIPT. The detection of these subchromosomal copy-
number variations (CNVs) requires a higher resolution
than chromosomal aneuploidy detection because the af-
fected region is much smaller. Initial studies used mater-
nal plasma DNA sequencing for detecting a microdeletion
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Hypothesis 1 Hypothesis 2
(A) (B) (C)
TRENDS in Molecular Medicine 
Figure 2. Noninvasive prenatal testing for aneuploidies. (A) Random massively-parallel sequencing; (B) SNP-allelic ratio-based targeted sequencing approach; (C) non-
SNP-allelic ratio-based chromosome selective targeted sequencing approach. Abbreviations: chr, chromosome; FORTE, fetal-fraction optimized risk of trisomy evaluation;
NATUS, next-generation aneuploidy test using SNPs.
Review Trends in Molecular Medicine February 2015, Vol. 21, No. 2
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Figure,1.,MPS$procedure.$Extracted$from:$Wong$A$&$Lo$D$(2015).,
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AddiBonal,step,in,dyzigoBc,fetus,
fetal DNA fraction,2 we could further determine if one or both
f tuses were affected. Although the method cannot pinpoint
which ne of the twins had aneuploidy, the aneuploidy
assessment of the twin fetuses could be made with greater
certainty to justify the need for invasive conﬁrmatory testing.
Because of the proof-of-principle nature of this study,
further studies with larger sample size are needed. For case
02, trisomy 18 wa diagnosed postnatally; hence, fetal tissues
were not available for analysis in this study. However, our
results were consistent with the postnatal diagnosis.
Although the noninv sive twin zygosity test provides useful
information for interpreting the PS-NIPT for fetal
chromosomal aneuploidy testing, it is an added procedure
and additional costs are involved. With the rapid reduction in
sequencing costs, the zygosity test could be considered as an
optional quality control step for additional reassurance in
A
B
Figure 3 Determination of the number of twin fetus(es) with chromosomal aneuploidy. The red line shows the expected relationship between
the maternal plasma genomic representation of the aneuploid chromosome and the fetal DNA fraction. The dashed line marks the genomic
representation of the affected twin pregnancy. The black solid lines mark the fetal DNA percentage estimated for each fetus of the dizygotic
twin pair and the combined fetal DNA percentage from both fetuses. The genomic representation and fetal DNA percentage values for the
seven male singleton control pregnancies are depicted by squares. (A) Plot of %chr21 and fetal DNA percentage values for case 01. The
correlation line for %chr21 intercepts with the observed genomic representation o the affected twin pregnancy when the fractional fetal DNA
concentration is 15.4%. (B) Plot of %chr18 and fetal DNA percentage values for case 02. The correlation line for %chr18 intercepts with the
observed genomic representation of the affected twin pregnancy when the fractional fetal DNA concentration is 11.9%. Each plot suggests that
there is only one fetus affected by aneuploidy in each twin pair
T. Y. Leung et al.680




(22), such as twin–twin transfusion, than dizygotic
twins. Furthermore, the zygosity of twins has implica-
tions for pren tal genetic testing. Monozygotic twins
can be assessed like singleton pregnancies, w ereas
each fetus of a dizygotic twin pair needs to be assessed
individually.
Noninvasive prenatal diagnosis of fetal chromo-
somal aneuploidies as been ac iev d with th use of
massively parallel sequencing ofmaternal plasmaDNA
(20, 21, 23, 24). Canick et al. (25) recently applied the
protocol, which had originally been validated with sin-
gleton pregnancies, for the testing of multifetus preg-
nancies. These authors showed that increased amounts
of chromosome 21 DNAmolecules were present in the
maternal plasma for 2 sets of twins in which both fe-
tuses had Down syndrome and for 5 sets of twins in
which only one of the twin fetuses had Down syn-
drome. Down syndrome was correctly excluded in 17
sets of twins and 2 sets of triplets who had been con-
firmed to be karyotypically normal. Although the data
are encouraging, it would be ideal if the zygosities of the
twins had been known before aneuploidy testing. The
diagnostic sensitivity of DNA sequencing of maternal
Fig. 4. Mean apparent fractional fetal DNA concentrations across blocks of 1000 consecutive informative SNPs.
Solid lines show the apparent fractional fetal DNA concentrations across 1000-SNP blocks in monozygotic twin cases
(A) and dizygotic twin cases (B). The x axis represents the informative SNPs arranged in chromosome numerical order.
The y axis represents the apparent fractional fetal DNA concentration per 1000 informative SNPs. Solid lines show the
results for each case. Gray shadowing shows the results of the computer simulation analys s of the background stochastic
variation. Dashed lines show the maximum and minimum values of the predicted stochastic variation. The proportion of
data points outside the boundaries is given at the top of each plot. Case numbers are given in th upper right
corner.
Table 2. Fractional fetal DNA concentration of
member of a dizygotic t in pair resolved by the
b nomial-mixture model or by use of info mative






Twin I Twin II Twin I Twin II
6774 7.0 11.4 7.9 10.9
6881 14.0 8.6 11.6 10.0
6905 13.9 7.0 11.2 7.8
8103 18.6 11.0 18.2 12.4
Noninvasive Prenatal Determination of Twin Zygosity
Clinical Chemistry 59:2 (2013) 433
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in$all$ the$ informa:ve$SNPs$ (1).$Their$mean$ (for$every$1000$ informa:ve$
SNPs$ on$ con:guous$ genomic$ blocks)$ would$ demonstrate$ no$ regional$
varia:on$(2).$
DizygoBc,twins:,
SNP,1,
Mother:$AA$
Fetus$I:$AB$
Fetus$II:$AB$
SNP,2,
Mother:$AA$
Fetus$I:$AA$
Fetus$II:$AB$
